Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Nine Months Ended

September 30,

2008 2007

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income (loss) $210,962 $(235,886)

Adjustments to reconcile net

income to net cash provided by

operating activities:

Deferred income tax

(benefit) expense (9,409) 8,750

Shortfall tax benefits from

stock-based compensation (451) (222)

Depreciation and amortization 128,772 101,206

Stock-based compensation expense 32,543 34,940

Gain on sale of investment - (5,791)

Gain on forgiveness of debt - (5,319)

Loss on disposals of property

and equipment 2,740 2,873

Impairment charges 1,164 -

Other (396) 180

Changes in operating

assets and liabilities:

Receivables (74,258) (26,218)

Inventory (14,557) (1,881)

Other assets (99,008) (28,552)

Accounts payable and

accrued expenses 34,526 380,776

Other liabilities 70,
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... BOZEN, Italy, November 4 Health Robotics today ... Workflow Engine at,the American Society of Health-System Pharmacists, Mid-Year ... the i.v.SOFT Workflow Engine,Health Robotics becomes the first and ... solution to fill the void of automated process control ...
... , SEOUL, South Korea, Nov. 4 RNL BIO Co., ... cell therapeutics announced today that it treated an American college ... gained her hearing back in two months after treatment. , ... music at University of Arizona was suffering from autoimmune hearing ...
... ... new treatment program for FIV and FELV , ... New York, N.Y. (PRWEB) November 4, 2009 -- IMULAN BioTherapeutics, LLC has developed ... to get LTCI for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Like Human ...
Cached Biology Technology:Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 2Health Robotics Announces December Launch of the i.v.SOFT(TM) Workflow Engine at ASHP in Las Vegas 3RNL BIO Rescues a College Student from Autoimmune Hearing Loss 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 3RNL BIO Rescues a College Student from Autoimmune Hearing Loss 4New Program Developed in the Fight Against Feline Aids 2
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has ... Market 2015-2019" report to their offering. ... is a technology used for the identification of individuals. ... a person such as nose, jaw edges, mouth, and ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... of its strategic plan, " Forging the Future A ... Genome Institute (DOE JGI) has positioned itself to provide the ... they can address pressing energy and environmental scientific challenges. ... the launch of the Emerging Technologies Opportunity Program (ETOP) ...
... Once famously described as "orphan diseases, too small to ... Hollywood drama "Lorenzo,s Oil," rare diseases are getting unprecedented ... research efforts and marketing new medicines that promise fuller ... conditions. That,s the finding of a major examination, ...
... own function by "accelerating and braking" is important basic knowledge ... cells are tweaked to produce more bioenergy. In a study ... Uppsala and Ume universities show a model of how cells, ... system similar to what can be found in today,s smartphones. ...
Cached Biology News:The DOE Joint Genome Institute expands capabilities via new partnerships 2The DOE Joint Genome Institute expands capabilities via new partnerships 3Cells must use their brakes moderately for effective speed control 2
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... technology incorporating the sophisticated DirectDrive architecture ... new Varian NMR System is undeniably ... ,The Varian NMR System features parallel ... channel, providing pulse sequence programming power ...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
... wells. ELISA.Specific for total MMP-3: Recognizes proMMP-3, ... with MMP-1, -2, -9. Range: 3.75-120 ng/ml. ... culture supernatant, serum, plasma and tissue samples.~ ... Category: Drug Screening & Cellular Assays, ...
Biology Products: